Quidel and Prodesse to promote molecular diagnostic test

Quidel will now have access to a new molecular product, particularly suited for the acute care laboratory market. The ProFlu+ test provides a complementary product offering to the Quidel QuickVue rapid influenza and RSV tests. As part of the agreement, Quidel earns a fee for all product placements. The agreement is said to strengthen Prodesse’s own sales efforts with acute care representation by the Quidel sales and marketing teams.

ProFlu+ is an FDA 510(k) cleared, real-time PCR, closed tube test that simultaneously detects influenza A, influenza B and respiratory syncytial virus (RSV), which together cause the vast majority of serious respiratory infections.

Caren Mason, president and CEO of Quidel, said: “Our acute care customers look for leadership from Quidel in influenza management. By co-promoting this product, we are providing an alternative solution to those seeking a molecular complement to their rapid testing program.”